Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 76 to 87 from a total of 87
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
Riastap 1 g |
CSL Behring GmbH |
PEI.H.04771.01.1 | 03.12.2009 | Rote-Hand-Brief: Haemocomplettan und Riastap (01.04.2019) |
|
Rixubis |
Baxter Innovations GmbH |
EU/1/14/970 | 19.12.2014 | |
|
Veyvondi |
Baxalta Innovations GmbH |
EU/1/18/1298 | 31.08.2018 | |
|
Vihuma |
Octapharma AB, Stockholm |
EU/1/16/1168 | 13.02.2017 | |
|
Voncento |
CSL Behring GmbH |
EU/1/13/857 | 12.08.2013 | |
|
Wilate 450 |
OCTAPHARMA GmbH |
PEI.H.01918.01.1 | 08.02.2005 | |
|
Wilate 500 |
OCTAPHARMA GmbH |
PEI.H.01918.03.1 | 22.12.2011 | |
|
Wilate 900 |
OCTAPHARMA GmbH |
PEI.H.01918.02.1 | 08.02.2005 | |
|
Wilate 1000 |
OCTAPHARMA GmbH |
PEI.H.01918.04.1 | 22.12.2011 | |
WILLFACT 500 I.E. |
LFB-Biomedicaments |
PEI.H.03530.02.1 | 24.12.2014 | |
WILLFACT 1000 I.E. |
LFB-Biomedicaments |
PEI.H.03530.01.1 | 15.05.2009 | |
WILLFACT 2000 I.E. |
LFB-Biomedicaments |
PEI.H.03530.03.1 | 24.12.2014 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
